MiMedx Group Inc (NASDAQ:MDXG)
| 5.76 Delayed Data As of May 26 |  +0.08 / +1.41%Today’s Change | 2.43 Today|||52-Week Range 6.42 | +107.19% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $667.0M |
Company Description
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
Contact Information
MiMedx Group, Inc. 1775 West Oak Commons Court NE Marietta Georgia 30062 |
Employees
Shareholders
| Other institutional | 28.95% |
| Individual stakeholders | 28.49% |
| Mutual fund holders | 17.53% |
Top Executives
| Joe Capper | Chief Executive Officer & Director |
| Ricci S. Whitlow | Chief Operating Officer & Executive Vice President |
| Peter M. Carlson | Chief Financial Officer |
| David H. Mason | Chief Medical Officer |
| John R. Harper | CTO, Senior VP-Research & Development |
